Health & Beauty

Montefiore-Einstein Participates at ASTRO 2016

Members of the Department of Radiation Oncology at Montefiore Einstein Center for Cancer Care and Albert Einstein College of Medicine's NCI-designated Albert Einstein Cancer Center is presenting new study findings at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO) that will advance treatment of pancreatic and anal cancers.

According to a media release, researchers will also lead a discussion about implementing a cost efficient workflow for treatment of the most advanced forms of throat cancer.

These are some of the highlights at ASTRO 2016, which is taking place at the Boston Convention Center through September 28.

"For too long people with pancreatic cancer have faced poor prognoses, with immunotherapies offering little hope," said Shalom Kalnicki, M.D., professor and chair, Department of Radiation Oncology, Montefiore-Einstein. "By combining radiation therapy and immunotherapy we have obtained promising results that indicate that we can change how the body reacts to cancer cells and that we have the potential to enhance the effectiveness of immunotherapies in fighting diseases that are difficult to treat. We are excited about this progress, which we believe represents the future of effective cancer therapies. We look forward to sharing these findings and presenting new recommendations for effectively treating several cancers."

Following are the oral presentations Montefiore-Einstein investigators will deliver at the meeting, which are embargoed until the time of presentation. Additionally, Dr. Kalnicki will be one of ten individuals honored with the ASTRO Fellows designation for his significant contributions to the field of radiation oncology and improving patient outcomes.

Investigators are available for interviews specific to their presentation or to comment on other reports of interest at ASTRO 2016.

1. Epigenetic Priming and High-Dose Radiation for Enhanced Immune Response in Pancreatic Cancer - Presented by Kartik Mani, M.D., Ph.D., chief resident, Department of Radiation Oncology, Montefiore Einstein Center for Cancer Care. Tuesday, September 27 at 2:55pm. Biology Track - Room #257 A/B - Presentation 196.

-Immunotherapy aims to boost the body's immune system. So far it has helped improve outcomes in lung cancer, bladder cancer and melanoma. However, people with cancers such as pancreatic cancer, ovarian cancer and triple negative breast cancer have not benefited from this treatment. Those cancers do not trigger an immune response because their cells don't display key proteins (antigens) that the immune system needs to recognize in order to launch an attack. Montefiore-Einstein researchers speculated that the genes responsible for making these antigens had been epigenetically "turned off" so the researchers developed a novel one-two punch to enhance the effectiveness of immunotherapy: (1) a drug to "turn on" the genes that cause cancer cells to make antigens; and (2) a single high dose of radiation. The researchers found that this combination significantly bolstered the immune response against pancreatic cancer cells. This novel approach offers new hope for people suffering from pancreatic cancer and holds promise for making immunotherapy effective against diseases that are difficult to treat.

2. Radiation Therapy Compliance/Quality Assurance (QA) in Two Phase II Trials of Cetuximab Plus Combined Modality Therapy (CMT) including Chemotherapy and Radiation Therapy (RT) for Squamous Cell Carcinoma of the Anal Cancer (SCCAC) in Patients with (AMC045) - Presented by Madhur Garg, M.D., clinical director, Department of Radiation Oncology, Montefiore Einstein Center for Cancer Care and professor of clinical radiation oncology at Einstein. Tuesday, September 27 at 5:15pm. Gastrointestinal Track - Room #160 A/B/C - Presentation 239

-Cases of anal cancer are on the rise, with most people being diagnosed in their early 60s. Effective treatments exist for this disease, but some patients--particularly people who are HIV positive--are not being cured. Montefiore-Einstein researchers led two national studies, involving both HIV-negative and HIV-positive patients, that evaluated dosages of targeted therapies combined with chemotherapy and radiation. The studies found that HIV-positive patients can tolerate treatment well and have comparable cure rates with non-HIV patients.

3. Patterns of Failure and Origin of Recurrence on PET/CT for Laryngeal Cancer Patients Treated with Definitive IMRT- Discussion led by Rafi Kabarriti, M.D., attending physician, Department of Radiation Oncology, Montefiore Einstein Center for Cancer Care and assistant professor of radiation oncology at Einstein. Wednesday, September 28 at 11am. Physics Track - Room #052 B - Presentation 1135.

-New therapies have improved treatment of laryngeal cancer and enhanced the quality of life for patients with this disease, but treatment of advanced laryngeal cancers remains a challenge. This is largely because of cancer recurrence. Advanced laryngeal cancers have cure rates of only 62 percent compared with cure rates of around 90 percent for less-advanced cases. To gain insight into why treatment for advanced laryngeal cancer often fails, Montefiore-Einstein researchers studied patients whose laryngeal tumors had recurred following intensity-modulated radiation therapy (IMRT). Using CT-PET scans and software tools, the researchers pinpointed where in the treated tumor the cancer recurrence had originated. Eighty six percent of the recurrences originated in tumor regions treated with high-dose radiation. This finding will help identify patients who are at high risk of recurrence and lays the groundwork for a clinical trial using this novel treatment regimen.

More information:

www.montefiore.org

www.einstein.yu.edu

((Comments on this story may be sent to newsdesk@closeupmedia.com))

THE DAILY VIEW

  • Alexandra Scarborough
    Tea Forté Introduces ‘Matcha’ Collection

    Convenience meets tradition in Tea Forté’s new Ceremonial Matcha Bowl Set and the Matcha Single Steeps.

    The company said its spring harvested, shade grown, stone ground, organic matcha tea is best served in a centuries-old Japanese tea ceremony called chanoyu: a preparation technique known for its centering meditative qualities.

    "The launch of Tea Forté's Matcha collection represents our continued commitment to wellness and cultivating all the potential mental and physical health benefits of tea," says Tea Forté CEO Michael Gebrael. "In addition to our high quality Pure Matcha, we've also blended four distinct flavored Matcha varieties. Prepackaged in pouches measured out for a single serving, our Single Steeps Matcha is ideal for the office, travel, or to keep with you for a boost anytime."

    Tea Forté noted its handcrafted ceremonial tea bowl, handmade bamboo whisk and measuring ladle “encourages serene enjoyment of our premium Kosher, gluten-free and vegan matcha blends.” These include: Pure Matcha, Chocolate Matcha, Coconut Matcha, Ginger Matcha, and Chai Matcha.

    According to a release, in addition to its distinctive taste, matcha is prized for its health benefits. Steeped green tea contains only the antioxidants that can be extracted in water, while with matcha, the whole leaf is consumed.

    Available now in select stores and online at teaforte.com.

 

 

QUICK 5


Expedia.com has released a year-end look at U.S. traveler behavior and trends for 2017, analyzing data to identify the most in-demand destinations, hotels, activities and more.

Among other insights, the roundup revealed:

  1. Labor Day was the busiest weekend for car rental
  2. Disney Theme Parks topped the list of things to do
  3. The average hotel stay was two nights
  4. Top destinations based on 2017 air travel included major global cities like New York, London and Bangkok
  5. Popular tourist destinations included Orlando, Cancun and Las Vegas